返回
Guangzhou Innogen Pharmaceutical Group Co., Ltd（02591.HK）價格
02591.HK 股價走勢圖
INNOGEN-B (02591.HK)
Guangzhou Innogen Pharmaceutical Group Co., Ltd
HK$30.98
-3.18%
$-1.01
休市： Jan 16, 16:00:00 HKT
關鍵數據
前收市價
$31.02
開盤價
$32
當日範圍
$30.86 - $32.78
52週區間
$28.4 - $74
交易量
410.8K
平均成交量
667.1K
每股盈餘 (TTM)
-0.54
股息收益率
--
市值
$13.0B
什麼是 INNOGEN-B？
Guangzhou Innogen Pharmaceutical Group Co., Ltd. engages in the production and distribution of pharmaceutical products. The company is headquartered in Guangzhou, Guangdong and currently employs 105 full-time employees. The company went IPO on 2025-08-15. The firm is primarily engaged in the commercialization of innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. The firm is dedicated to developing therapies for diabetes and other metabolic diseases. The Company’s core product, Efsubaglutide Alfa (brand name: Diabegone), is used for the treatment of type 2 diabetes (T2D). The Company’s primary pipeline drug candidates include YN014, YN401, YN209, YN203, and YN202. The firm principally conducts its businesses in the domestic market.
